Review Article

Gynecomastia: Etiologies, Clinical Presentations, Diagnosis, and Management

Authors: Barry Ladizinski, MD, Kachiu Cecilia Lee, MD, MPH, F.N.U. Nutan, MD, H. William Higgins, MD, Daniel G. Federman, MD

Abstract

Gynecomastia is a common finding that is present in up to 57% of men. It is caused by proliferation of the mammary glands, which leads to the development of dense subareolar tissue. The condition results from both physiologic (eg, hypogonadism, altered estrogen-to-androgen ratio) and nonphysiologic (eg, drugs, herbal products) causes. Most cases are benign and resolve spontaneously. Treatment is usually unnecessary, although there are specific signs and symptoms that warrant further workup. Psychosocial effects also are of concern, particularly among adolescents. Knowledge of the possible causes of gynecomastia and a thoughtful approach to the patient presenting with this condition can lead to improved outcomes and patient satisfaction. This concise review of the common presentation, etiologies, diagnosis, and treatment of gynecomastia should aid healthcare professionals who may encounter these patients in their practices.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Krause W. Drug-inducing gynaecomastia—a critical review. Andrologia. 2012; 44: 621–626.
 
2. Narula HS, Carlson HE. Gynecomastia. Endocrinol Metab Clin North Am. 2007; 36: 497–519.
 
3. Al-Allak A, Govindarajulu S, Shere M, et al. Gynaecomastia: a decade of experience. Surgeon. 2011; 9: 255–258.
 
4. Daniels IR, Layer GT. Gynaecomastia. Eur J Surg. 2001; 167: 885–892.
 
5. Bembo SA, Carlson HE. Gynecomastia: its features, and when and how to treat it. Cleve Clin J Med. 2004; 71: 511–517.
 
6. Niewoehner CB, Nuttal FQ. Gynecomastia in a hospitalized male population. Am J Med. 1984; 77: 633–638.
 
7. Nuttall FQ. Gynecomastia as a physical finding in normal men. J Clin Endocrinol Metab. 1979; 48: 338–340.
 
8. Georgiadis E, Papandreou L, Evangelopoulou C, et al. Incidence of gynaecomastia in 954 young males and its relationship to somatometric parameters. Ann Hum Biol. 1994; 21: 579–587.
 
9. Hassan HC, Cullen IM, Casey RG, et al. Gynaecomastia: an endocrine manifestation of testicular cancer. Andrologia. 2008; 40: 152–157.
 
10. Bannayan GA, Hajdu SI. Gynecomastia: clinicopathologic study of 351 cases. Am J Clin Pathol. 1972; 57: 431–437.
 
11. Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med. 2007; 357: 1229–1237.
 
12. Hines SL, Tan WW, Yasrebi M, et al. The role of mammography in male patients with breast symptoms. Mayo Clin Proc. 2007; 82: 297–300.
 
13. Wiesman IM, Lehman JA Jr, Parker MG, et al. Gynecomastia: an outcome analysis. Ann Plast Surg. 2004; 53: 97–101.
 
14. Colombo-Benkmann M, Buse B, Stern J, et al. Indications for and results of surgical therapy for male gynecomastia. Am J Surg. 1999; 178: 60–63.
 
15. Al-Qattan M, Hassanain J, Mahmoud S, et al. On the neglected entity of unilateral gynecomastia. Ann Plast Surg. 2005; 55: 255–257.
 
16. Ersoz H, Onde ME, Terekeci H, et al. Causes of gynaecomastia in young adult males and factors associated with idiopathic gynaecomastia. Int J Androl. 2002; 25: 312–316.
 
17. Deepinder F, Braunstein GD. Drug-induced gynecomastia: an evidence-based review. Expert Opin Drug Saf. 2012; 11: 779–795.
 
18. Eckman A, Dobs A. Drug-induced gynecomastia. Expert Opin Drug Saf. 2008; 7: 691–702.
 
19. Block SL. The possible link between gynecomastia, topical lavender, and tea tree oil. Pediatr Ann. 2012; 41: 56–58.
 
20. Henley DV, Lipson N, Korach KS, et al. Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med. 2007; 356: 479–485.
 
21. Kakisaka Y, Ohara T, Tozawa H, et al. Panax ginseng: a newly identified cause of gynecomastia. Tohoku J Exp Med. 2012; 228: 143–145.
 
22. Korde LA, Zujewski JA, Kamin L, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010; 28: 2114–2122.
 
23. Martinez J, Lewi JE. An unusual case of gynecomastia associated with soy product consumption. Endocr Pract. 2008; 14: 415–418.
 
24. Messina M. Soybean isoflavone exposure does not have feminizing effects on men: a critical examination of the clinical evidence. Fertil Steril. 2010; 93: 2095–2104.
 
25. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004; 34: 513–554.
 
26. Emory TH, Charboneau JW, Randall RV, et al. Occult testicular interstitial-cell tumor in a patient with gynecomastia: ultrasonic detection. Radiology. 1984; 151: 474
 
27. Hendry WS, Garvie WH, Ah-See AK, et al. Ultrasonic detection of occult testicular neoplasms in patients with gynaecomastia. Br J Radiol. 1984; 57: 571–572.
 
28. Mudde AH, Haak A, Kruyt RH. Ultrasonic detection of occult Leydig cell tumours in two patients with gynaecomastia. Neth J Med. 1987; 31: 72–76.
 
29. Haas GP, Pittaluga S, Gomella L, et al. Clinically occult Leydig cell tumor presenting with gynecomastia. J Urol. 1989; 142: 1325–1327.
 
30. Mellor SG, McCutchan JD. Gynaecomastia and occult Leydig cell tumour of the testis. Br J Urol. 1989; 63: 420–422.
 
31. Goldman RD. Drug-induced gynecomastia in children and adolescents. Can Fam Physician. 2010; 56: 344–345.
 
32. Dardick KR. Holiday gynecomastia related to marijuana? Ann Intern Med. 1993; 119: 253
 
33. Thompson DF, Carter JR. Drug-induced gynecomastia. Pharmacotherapy. 1993; 13: 37–45.
 
34. Cates W Jr, Pope JN. Gynecomastia and cannabis smoking. A nonassociation among US Army soldiers. Am J Surg. 1977; 134: 613–615.
 
35. Brinton LA. Breast cancer risk among patients with Klinefelter syndrome. Acta Paediatr. 2011; 100: 814–818.
 
36. Brinton LA, Carreon JD, Gierach GL, et al. Etiologic factors for male breast cancer in the U.S. Veterans Affairs medical care system database. Breast Cancer Res Treat. 2010; 119: 185–192.
 
37. Johansen Taber KA, Morisy LR, Osbahr AJ 3rd, et al. Male breast cancer: risk factors, diagnosis, and management. Oncol Rep. 2010; 24: 1115–1120.
 
38. Krause W. Male breast cancer—an andrological disease: risk factors and diagnosis. Andrologia. 2004; 36: 346–354.
 
39. Maksimovic S. Bilateral breast carcinoma in patients with Klinefeleter syndrome: report of case. Med Arch. 2010; 64: 250–252.
 
40. Zygogianni AG, Kyrgias G, Gennatas C, et al. Male breast carcinoma: epidemiology, risk factors and current therapeutic approaches. Asian Pac J Cancer Prev. 2012; 13: 15–19.
 
41. Plourde PV, Kulin HE, Santner SJ. Clomiphene in the treatment of adolescent gynecomastia. Clinical and endocrine studies. Am J Dis Child. 1983; 137: 1080–1082.
 
42. Bedognetti D, Rubagotti A, Conti G, et al. An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients. Eur Urol. 2010; 57: 238–245.
 
43. Fradet Y, Egerdie B, Andersen M, et al. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur Urol. 2007; 52: 106–114.
 
44. Di Lorenzo G, Perdona S, De Placido S, et al. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. J Urol. 2005; 174: 2197–2203.
 
45. Perdona S, Autorino R, De Placido S, et al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol. 2005; 6: 295–300.
 
46. Lawrence SE, Faught KA, Vethamuthu J, et al. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J Pediatr. 2004; 145: 71–76.
 
47. Derman O, Kanbur NO, Kutluk T. Tamoxifen treatment for pubertal gynecomastia. Int J Adolesc Med Health. 2003; 15: 359–363.
 
48. Alagaratnam TT. Idiopathic gynecomastia treated with tamoxifen: a preliminary report. Clin Ther. 1987; 9: 483–487.
 
49. Jones DJ, Holt SD, Surtees P, et al. A comparison of danazol and placebo in the treatment of adult idiopathic gynaecomastia: results of a prospective study in 55 patients. Ann R Coll Surg Engl. 1990; 72: 296–298.
 
50. Saltzstein D, Sieber P, Morris T, et al. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis. 2005; 8: 75–83.
 
51. Plourde PV, Reiter EO, Jou HC, et al. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2004; 89: 4428–4433.
 
52. Hanavadi S, Banerjee D, Monypenny IJ, et al. The role of tamoxifen in the management of gynaecomastia. Breast. 2006; 15: 276–280.
 
53. Wassersug RJ, Oliffe JL. The social context for psychological distress from iatrogenic gynecomastia with suggestions for its management. J Sex Med. 2009; 6: 989–1000.